RxDoctor Payments Data

David Quarles, NP

Family · Flowood, MSNPI 1235436577

Payments from drug & device makers

$4,936in general payments, 2019–2025

Across 167 payments — averaging $29.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Madrigal Pharmaceuticals$2K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$644
  • Phathom Pharmaceuticals, Inc.$294
  • E.r. Squibb & Sons, L.L.C.$262
  • AbbVie$215
  • Ipsen Biopharmaceuticals, Inc$179
  • plus $921 from 18 others

What the payments were for

  • Consulting fees$1453%
  • Speaking & faculty fees$1,62033%
  • Food & beverage$3,17164%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,936 in reported general payments places this provider in the 90th percentile of 3,007 family providers in Mississippi.

See all family providers in Mississippi

Medicare billing

Part B allowed, 2024
$99,121
Medicare patients
671
Services billed
2,230

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RezdiffraResmetirom46$179,553
XifaxanRifaximin11$29,516
LinzessLinaclotide12$8,097
Colesevelam Hcl30$3,795
Ursodiol28$2,018
Sucralfate47$1,827
Famotidine94$1,078
Ondansetron OdtOndansetron26$881
Lactulose11$647
Dicyclomine Hcl42$621
Omeprazole65$494
Pantoprazole Sodium58$493
Metronidazole30$238
Ciprofloxacin Hcl23$161
Spironolactone20$125

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Madrigal PharmaceuticalsRezdiffra$2,421$179,55346 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$644$29,51611 claims
AbbVieLinzess$215$8,09712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,007 family providers in Mississippi.

Other family in Flowood

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →